The latest biotech news - Labiotech.eu

Home News and Trends Page 342

Latest Posts

Biofuels

News and Trends 20 Oct 2015

Scaling-up Biofuels: The Challenges of Giant Bioreactors

Global Bioenergies from France is building a proto-plant for Isobutene production in Germany, with partnerships with car manufacturer Audi. Now their plant will receive a 5,000 Litre fermentation tank, after overcoming the challenging process of scaling-up second generation biofuel production. Global Bioenergies’ return to first generation biofuel production has already been discussed as a bit […]

October 20, 2015 - 3 minutesmins - By Dani Bancroft

Karolinska Institutet Science Park stem cells

News and Trends 20 Oct 2015

First-ever in utero Stem Cell Trial to be conducted by Karolinska Institutet

The Karolisnka Institutet (Sweden) is ready to make History by conducting the first study involving the transplantation of stem cells into unborn babies. The treatment aims to strengthen the bone by producing collagen in infants with the brittle-bone disease Osteogenesis imperfecta in utero. The study is to be coordinated by the Karolinska Institute but to […]

October 20, 2015 - 3 minutesmins - By Lourdes Riquelme

Affimed

News and Trends 19 Oct 2015

Secret Shareholder racks up another €19.2M for Affimed’s Cancer Tandem Antibodies

Affimed Therapeutics is a clinical-stage biopharmaceutical company from Heidelberg (Germany) which is developing highly targeted cancer immunotherapies for some leukemias and Hodgkin’s Lymphoma. An undisclosed shareholder has just increased its position in the company by purchasing an additional 3.3 million shares, leading to a total of €19.2M private investment. Affimed Therapeutics is a NASDAQ-listed biotech […]

October 19, 2015 - 2 minutesmins - By Julie Lellouche

Enfleurage

News and Trends 19 Oct 2015

Synbio Perfumery: Making Smells and Flavors with Microbes

Isobionics is a biotech from the Netherlands that specializes in synthetic bio-production of natural essential oils and flavorings for use in the food, perfume and detergent industry. On the other hand, Evolva, from Basel, are estimated to produce up to $500M worth of synthetic vanilla essence for the industry each year. Using bacteria and yeast […]

October 19, 2015 - 4 minutesmins - By Dani Bancroft

autumn best week

News and Trends 17 Oct 2015

What Happened this Week? Top 15 EU VCs, Roche + Novartis, Algae for Aerospace Biofuel

Monday: Who is the Leader in the Vaccination Ecosystem – is it (still) Europe? Tuesday: The Top 15 European Biotech VCs Wednesday: No, Novartis and Roche won’t merge (yet)! Thursday: Spanish connection: VC leads Biotech series A Fund to cure Rare Neurodegenerative Disease Friday: Bavarian Facility can now grow Global Strains of Algae for Aerospace Biofuel […]

October 17, 2015 - 1 minutemin - By Philip Hemme

Algae1

News and Trends 16 Oct 2015

Bavarian Facility can now grow Global Strains of Algae for Aerospace Biofuel Production

The Technology University of Munich (TU München) has built a unique global-climate simulating Algal plant on the Ludwig Bölkow Campus in Ottobrunn (Bavaria). Able to cultivate algal strains from all over the world, the research team hopes this will allow them to study and discover new types to be exploited by Biotechs for biofuel production, […]

October 16, 2015 - 3 minutesmins - By Dani Bancroft

ADVERTISEMENT

berlin banner 2

News and Trends 16 Oct 2015

Biotech of the week: Mologen, the Largest Publicly-listed Biotech of Berlin

This week, we’re leaving Paris and heading East to a city that’s 9 times bigger than the capital of France, it’s also the city we all call home here at Labiotech, Berlin. When someone thinks of Berlin, they think of the wall, the Fernsehturm (television tower) and its amazing nightlife (I can personally agree with this 😉 […]

October 16, 2015 - 2 minutesmins - By Philip Hemme

Ablynx

News and Trends 15 Oct 2015

Ablynx richly rewarded for MSD’s Nanobody Proof in Immuno-Oncology

Ablynx – the Belgian nanobody biotech (which uses monoclonal antibodies of Alpacas), has now achieved it’s first pre-clinical milestone in its immuno-oncology partnership with MSD (Merck & Co). Now Ablynx has achieved proof of concept for one of the 17 Nanobodies being studied. Ablynx has therefore received the first €3.5M in milestone payments from MSD […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

Neurodegenerative disease

News and Trends 15 Oct 2015

Neurodegenerative Disease in the UK: Takeda, NIHR & UCL Research Collaboration

Takeda Cambridge (the UK subsidiary of global biotech Takeda Pharmaceuticals) will now collaborate with University College London‘s Institute for Neurology and their NHS teaching hospital to search for novel gene targets with significance in neurodegenerative disease. Takeda has already got massive Alzheimer‘s clout in the industry for its blockbuster Galantamine Hydrobromide (branded REMINYL in Japan), […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

YSIOS

News and Trends 15 Oct 2015

Spanish connection: VC leads Biotech series A Fund to cure Rare Neurodegenerative Disease

Minoryx Therapeutics is a Barcelona based Rare-disease specialist who has a panel of orphan-drug experts for their discovery program. Now backed in a €19.4M Series A round from leading VC firms Ysios (No 15 in our top EU VCs) and Roche Venture Fund, Minoryx will have the well-needed cash to push for further R&D of their […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

Neuroblastoma1

News and Trends 14 Oct 2015

High-Risk Infant Cancer: Nature publishes on a New and Reliable Biomarker from Cologne

New Oncology from Cologne (Germany) is a biotech which today published a paper in Nature on tumor-profile recognition of cancer of the sympathetic nervous system (Neuroblastoma) in conjunction with the latest research at the University of Cologne. The research team has found a new way to diagnose infants with the deadly high-risk version of Neuroblastoma, which […]

October 14, 2015 - 4 minutesmins - By Dani Bancroft

innate pharma cover

News and Trends 14 Oct 2015

Innate Pharma receives $5M from its Monster-deal with BMS

This milestone payment from Bristol-Myers Squibb is part of the lirilumab licensing agreement, the monster immuno-oncology deal of €408M ($465M) signed in July 2011. This payment was triggered by the dosing of the first patient in a phase II trial of the monoclonal antibody drug lirilumab, in combination with rituximab in patients with relapsed/refractory or […]

October 14, 2015 - 2 minutesmins - By Philip Hemme

ADVERTISEMENT